Sirolimus - Pfizer

Drug Profile

Sirolimus - Pfizer

Alternative Names: AY 22989; CYPHER; CYPHER SELECT PLus; NEVO; NPC-12; NPC-12G; NSC 226080; NSC 606698; Rapalimus; Rapamune; Rapamycin

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Cordis Corporation; Food and Drug Administration; Le Bonheur Children's Hospital; National Center for Advancing Translational Sciences; Nobelpharma; Pfizer; Wyeth
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis; Lymphangioleiomyomatosis; Renal transplant rejection
  • Phase III Fibroma
  • Phase II Systemic lupus erythematosus
  • Discontinued Autosomal dominant polycystic kidney disease; Mycoses

Most Recent Events

  • 09 May 2017 Pfizer terminates a phase III trial in Renal transplant rejection in USA as the collaborator stopped the study (PO) (NCT01166724)
  • 01 Oct 2016 Nobelpharma completes a phase III trial in Fibroma (facial angiofibroma in tuberous sclerosis complex; In children, In adolescents, In adults, In the elderly) in Japan (NCT02635789)
  • 01 Jul 2016 Le Bonheur Children's Hospital and Pfizer complete a phase-I trial in Fibroma (In children, In adolescents, In adults) in USA (NCT01853423)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top